An Observational Study of Chinese Adults with Relapsed/refractory Philadelphia-negative Acute Lymphoblastic Leukemia

Overview

Journal Int J Hematol Oncol

Date 2018 Nov 9

PMID 30405901

Citations 3

Authors

Jun Ma

Ting Liu

Jie Jin

Jianda Hu

Qifa Liu

Jianxiang Wang

Zhixiang Shen

Xin Du

Bin Jiang

Xianhua Meng

Affiliations

Soon will be listed here.

Abstract

Aim: Chinese adults with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph- ALL) have poor outcomes.

Patients & Methods: We conducted a nationwide, retrospective, observational study to assess outcomes in this patient population.

Results: Of the 270 enrolled patients, 31% of patients at last salvage achieved complete remission (CR) or CR with partial hematologic recovery (CRh), with median time to CR/CRh of 30 days and median CR/CRh duration of 2.7 months. The CR/CRh rate was more favorable with earlier versus later lines of salvage (41, 24 and 17% at first, second and third or later salvages, respectively).

Conclusion: This dataset serves as an important reference of real-world outcomes using currently available chemotherapy regimens for high-risk Chinese adults with relapsed/refractory Ph- ALL.

Citing Articles

A pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from China.

Gong X, Fang Q, Gu R, Qiu S, Liu K, Lin D Haematologica. 2024; 109(10):3146-3156.

PMID: 38235508 PMC: 11443404. DOI: 10.3324/haematol.2023.284228.

Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.

Fujishima N, Uchida T, Onishi Y, Jung C, Goh Y, Ando K Int J Hematol. 2019; 110(6):709-722.

PMID: 31655984 DOI: 10.1007/s12185-019-02749-0.

Welcome to Volume 8 of the .

Straiton J Int J Hematol Oncol. 2019; 8(1):IJH11.

PMID: 30863528 PMC: 6410014. DOI: 10.2217/ijh-2018-0012.

References

Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M . Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012; 13(4):403-11. DOI: 10.1016/S1470-2045(11)70386-2. View

Gokbuget N, Hoelzer D, Arnold R, Bohme A, Bartram C, Freund M . Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2001; 14(6):1307-25, ix. DOI: 10.1016/s0889-8588(05)70188-x. View

Liu L, Jiao W, Zhang Y, Qu Q, Li X, Wu D . Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute.... Leuk Res. 2015; 39(3):323-8. DOI: 10.1016/j.leukres.2015.01.003. View

Martinelli G, Boissel N, Chevallier P, Ottmann O, Gokbuget N, Topp M . Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter.... J Clin Oncol. 2017; 35(16):1795-1802. DOI: 10.1200/JCO.2016.69.3531. View

Matsumura T, Kami M, Yamaguchi T, Yuji K, Kusumi E, Taniguchi S . Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: retrospective survey involving 256 patients in Japan. Leukemia. 2012; 26(7):1482-6. DOI: 10.1038/leu.2012.11. View

Bassan R, Gatta G, Tondini C, Willemze R . Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol. 2004; 50(3):223-61. DOI: 10.1016/j.critrevonc.2003.11.003. View

Yilmaz M, Richard S, Jabbour E . The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol. 2015; 6(5):253-61. PMC: 4556970. DOI: 10.1177/2040620715596715. View

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

Tavernier E, Boiron J, Huguet F, Bradstock K, Vey N, Kovacsovics T . Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007; 21(9):1907-14. DOI: 10.1038/sj.leu.2404824. View

10.

Zugmaier G, Gokbuget N, Klinger M, Viardot A, Stelljes M, Neumann S . Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015; 126(24):2578-84. PMC: 4671107. DOI: 10.1182/blood-2015-06-649111. View

11.

Lee D, Kochenderfer J, Stetler-Stevenson M, Cui Y, Delbrook C, Feldman S . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385(9967):517-528. PMC: 7065359. DOI: 10.1016/S0140-6736(14)61403-3. View

12.

Katz A, Chia V, Schoonen W, Kelsh M . Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control. 2015; 26(11):1627-42. DOI: 10.1007/s10552-015-0657-6. View

13.

Lee K, Chow V, Weissman A, Tulpule S, Aldoss I, Akhtari M . Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults. Ther Clin Risk Manag. 2016; 12:1301-10. PMC: 5003562. DOI: 10.2147/TCRM.S84261. View

14.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

15.

Pui C, Robison L, Look A . Acute lymphoblastic leukaemia. Lancet. 2008; 371(9617):1030-43. DOI: 10.1016/S0140-6736(08)60457-2. View

16.

Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F . Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(11):1044-53. DOI: 10.1056/NEJMoa1605085. View

17.

Kantarjian H, Thomas D, OBrien S, Cortes J, Giles F, Jeha S . Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101(12):2788-801. DOI: 10.1002/cncr.20668. View

18.

Brentjens R, Davila M, Riviere I, Park J, Wang X, Cowell L . CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra38. PMC: 3742551. DOI: 10.1126/scitranslmed.3005930. View

19.

Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M . Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013; 119(15):2728-36. PMC: 3720844. DOI: 10.1002/cncr.28136. View

20.

Kantarjian H, DeAngelo D, Stelljes M, Martinelli G, Liedtke M, Stock W . Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(8):740-53. PMC: 5594743. DOI: 10.1056/NEJMoa1509277. View